Company Overview of Applied Genetic Technologies Corporation
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops genetic therapies to treat patients with inherited diseases. Its lead products consist of four ophthalmology development programs across three targets, including X linked retinoschisis (XLRS) that is in a Phase I/II clinical trials for the treatment of an inherited retinal disease; X-linked retinitis pigmentosa (XLRP), which is enrolling patients in a Phase I/II clinical trials; and achromatopsia (ACHM) that is enrolling patients in a Phase I/II clinical trials. Applied Genetic Technologies Corporation has collaboration agreements with Biogen MA, Inc.; 4D Molecular Therapeutics; and Synpromics Limited....
14193 NW 119th Terrace
Alachua, FL 32615
Founded in 1999
Key Executives for Applied Genetic Technologies Corporation
Chief Executive Officer, President and Director
Total Annual Compensation: $464.0K
Chief Financial Officer
Total Annual Compensation: $327.0K
Chief Medical Officer and Vice President
Total Annual Compensation: $381.5K
Chief Business Officer and Vice President
Total Annual Compensation: $314.2K
Chief Scientific Officer
Total Annual Compensation: $400.0K
Compensation as of Fiscal Year 2016.
Applied Genetic Technologies Corporation Key Developments
AGTC Announces Executive Changes
Nov 17 16
Applied Genetic Technologies Corporation announced the appointment of Michael Goldstein, M.D., M.B.A. as Chief Medical Officer (CMO) effective as of December 1, 2016. Dr. Goldstein will be responsible for leading the company’s clinical trials, providing medical oversight, and contributing to the overall strategic direction of the company. AGTC’s current Vice President and CMO, Jeffrey D. Chulay, M.D., DTM&H, will remain with the company as Executive Director of Clinical Strategy. Prior to joining AGTC, Dr. Goldstein held multiple roles of increasing responsibility with Eleven Biotherapeutics, including as Chief Medical Officer and Vice President of Clinical Research, where he worked with Eleven’s team to bring a novel treatment for dry eye disease from early research to a completed pivotal trial.
Applied Genetic Technologies Corporation Reports Unaudited Earnings Results for the First Quarter Ended September 30, 2016
Nov 8 16
Applied Genetic Technologies Corporation reported unaudited earnings results for the first quarter ended September 30, 2016. For the quarter the company’s total revenue was $11,806,000 compared to $11,062,000 a year ago. Income from operations was $3,389,000 against loss of $9,213,000 a year ago. Net income was $3,625,000 or $0.20 per basic and diluted share compared to loss of $9,123,000 or $0.53 per basic and diluted share a year ago.
Applied Genetic Technologies Corporation Presents at Stifel 2016 Healthcare Conference, Nov-15-2016 03:45 PM
Oct 28 16
Applied Genetic Technologies Corporation Presents at Stifel 2016 Healthcare Conference, Nov-15-2016 03:45 PM. Venue: Lotte New York Palace Hotel, New York, New York, United States. Speakers: Sue Washer, President and Chief Executive Officer.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|